Acuitas Lipid 17 (ALC-0315 retro-ester) · DCL0033Formulation & Performance
Formulation & In Vivo Data
Values shown are literature-reported results for the cited formulation and study conditions. DC Chemicals supplies the lipid only; these results do not guarantee performance in other formulations or experiments. For research use only.
Formulation components and molecular-weight conversion
A · Compound 17 : DSPC : Cholesterol : PEG-DMA = 50 : 10 : 38.5 : 1.5 mol%
Example 3, Table 3, printed pp.50–51 / PDF pp.52–53 · WO2017075531A1 · Patent
PEG-DMA: 2-[2-(ω-methoxy(polyethyleneglycol2000)ethoxy]-N,N-ditetradecylacetamide. Whole-conjugate grade-average MW and a verified DC catalog mapping are not assigned. Its mass and complete mass percentages remain unavailable until MW is entered.
Example 3, printed p.50 / PDF p.52; DC57005 / DCD-041 specifications · WO2017075531A1 · Patent
Formulation parameters
Example 1 gives general preparation ranges; the exact settings for the Compound 17 batch are not specified. Table 3 explicitly assigns Compound 17 to formulation A.
Examples 1–3, printed pp.46–50 / PDF pp.48–52 · WO2017075531A1 · Patent
LNP apparent pKa
Example 2, printed p.48 / PDF p.50; Table 3, printed p.51 / PDF p.53 · WO2017075531A1 · Patent
6.28
Measured in formulated LNPs by TNS fluorescence titration; pH at half-maximal fluorescence from a sigmoidal fit. No uncertainty is given for Compound 17.
Example 2; Table 3, Compound 17 · WO2017075531A1 · Patent
Cell experiment protocol
No Compound 17-specific cell-transfection or cytotoxicity experiment was reported in the examined patent.
Complete patent; Examples 1–3; Tables 2–3 · WO2017075531A1 · Patent
Animal experiment protocol
Example 1 gives general preparation ranges; the exact settings for the Compound 17 batch are not specified. Table 3 explicitly assigns Compound 17 to formulation A.
Table 3, printed p.51 (PDF p.53); Examples 1–3, printed pp.46–50 (PDF pp.48–52) · WO2017075531A1 · Patent
- Dissolve Compound 17, DSPC, cholesterol and PEG-DMA in ethanol at 50:10:38.5:1.5 mol%.
- Prepare the aqueous mRNA input as described below.
- Apply the published general mixing and processing ranges below; exact Compound 17 settings are not stated.
- Administer 0.3 or 1.0 mg mRNA/kg via the tail vein and collect liver at 4 h; retain the model limitations stated above.
- Weigh collected tissues, snap-freeze in liquid nitrogen and store at −80 °C until analysis.
- Homogenize ≈50 mg liver in a 2 mL FastPrep tube with a ¼-inch ceramic sphere and 500 µL room-temperature Glo Lysis Buffer: FastPrep24, 2 × 15 s at 6.0 m/s. Incubate 5 min at room temperature; dilute 1:4 in Glo Lysis Buffer.
- Mix 50 µL diluted homogenate with 50 µL SteadyGlo substrate; shake 10 s, incubate 5 min and read using CentroXS3 LB960. Normalize RLU to protein determined by BCA; use a QuantiLum recombinant-luciferase standard curve. Table 3 reports ng luciferase/g liver.
Lipid stock / organic phase
Ethanol; separate stock and combined organic-phase concentrations are not reported.
Ethanol; separate stock and combined organic-phase concentrations are not reported.
RNA aqueous input
FLuc mRNA L-6107, 0.2 mg/mL in 10–50 mM citrate buffer, pH 4, before mixing. Capped/polyadenylated; fully substituted with 5-methylcytidine and pseudouridine.
FLuc mRNA L-6107, 0.2 mg/mL in 10–50 mM citrate buffer, pH 4, before mixing. Capped/polyadenylated; fully substituted with 5-methylcytidine and pseudouridine.
Mixing / processing
Syringe-pump in-line mixing; organic:aqueous ≈1:5–1:3 (v/v); total flow >15 mL/min; total lipid:mRNA ≈10:1–30:1 (w/w). Dialysis to PBS, then 0.2 µm filtration. Exact Compound 17 settings, mixing temperature, dialysis duration and post-mixing concentrations are not reported.
Syringe-pump in-line mixing; organic:aqueous ≈1:5–1:3 (v/v); total flow >15 mL/min; total lipid:mRNA ≈10:1–30:1 (w/w). Dialysis to PBS, then 0.2 µm filtration. Exact Compound 17 settings, mixing temperature, dialysis duration and post-mixing concentrations are not reported.
Final administration
0.3 or 1.0 mg mRNA/kg, tail vein; PBS after dialysis. Final RNA/lipid concentrations and injection volume are not reported.
0.3 or 1.0 mg mRNA/kg, tail vein; PBS after dialysis. Final RNA/lipid concentrations and injection volume are not reported.
Storage and use
LNP storage and shelf life are not reported. Collected tissue was snap-frozen in liquid nitrogen and held at −80 °C until analysis; these are tissue-sample conditions.
LNP storage and shelf life are not reported. Collected tissue was snap-frozen in liquid nitrogen and held at −80 °C until analysis; these are tissue-sample conditions.
Table 3, printed p.51 (PDF p.53); Examples 1–3, printed pp.46–50 (PDF pp.48–52) · WO2017075531A1 · Patent
References
Ansell SM, Du X. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids. WO2017075531A1. Acuitas Therapeutics Inc. Published 4 May 2017. · WO2017075531A1 · Patent